CU20160001A7 - Una formulación farmacéutica que comprende una versión quimérica, una versión de fragmentos no humanos o humanizados del anticuerpo 9e4 - Google Patents
Una formulación farmacéutica que comprende una versión quimérica, una versión de fragmentos no humanos o humanizados del anticuerpo 9e4Info
- Publication number
- CU20160001A7 CU20160001A7 CUP2016000001A CU20160001A CU20160001A7 CU 20160001 A7 CU20160001 A7 CU 20160001A7 CU P2016000001 A CUP2016000001 A CU P2016000001A CU 20160001 A CU20160001 A CU 20160001A CU 20160001 A7 CU20160001 A7 CU 20160001A7
- Authority
- CU
- Cuba
- Prior art keywords
- range
- version
- present
- concentration
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Analytical Chemistry (AREA)
- Inorganic Chemistry (AREA)
Abstract
Una formulación farmacéutica que comprende una versión quimérica, una versión de fragmentos no humanos o humanizados el anticuerpo 9E4 (número de acceso ATCC, PTA-8221), o un fragmento de la misma que compite específicamente con la unión al antígeno con 9E4, en donde el anticuerpo está presenteen una concentración dentro del intervalo desde 10mg/ml hasta aproximadamente 50 mg/mL; amortiguador de citrato o de succinato que está presente en una concentración dentro del intervalo desde a 10mM hasta aproximadamente 30mM; uno o más azucares y polioles ("azúcar/poliol") seleccionado de: trehalosa presente en una concentración dentro del intervalo desde 220mM hasta aproximadamente 260mM, y una mezcla de sacarosa presente en una concentración dentro del intervalo desde 20mM hasta aproximadamente 40mM y manitol presente en una concentración dentro del intervalo desde 200mM hasta aproximadamente 220mM; y polisorbato 20 presente en una concentración dentro del intervalo desde 0.005% hasta aproximadamente 0.05% en peso; en donde la formulación se caracteriza por un pH dentro del intervalo desde 5.5 hasta aproximadamente 7. La presente invención también proporciona formulaciones de anticuerpos para uso en la profilaxis o tratamiento de sinucleinopatías incluyendo la enfermedad de Parkinson.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361843011P | 2013-07-04 | 2013-07-04 | |
US201461979886P | 2014-04-15 | 2014-04-15 | |
PCT/IB2014/062806 WO2015001504A2 (en) | 2013-07-04 | 2014-07-03 | Antibody formulations and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
CU20160001A7 true CU20160001A7 (es) | 2016-08-31 |
Family
ID=51355583
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CUP2017000039A CU20170039A7 (es) | 2013-07-04 | 2014-07-03 | Método de purificación del anticuerpo humanizado 9e4 |
CUP2016000001A CU20160001A7 (es) | 2013-07-04 | 2016-01-04 | Una formulación farmacéutica que comprende una versión quimérica, una versión de fragmentos no humanos o humanizados del anticuerpo 9e4 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CUP2017000039A CU20170039A7 (es) | 2013-07-04 | 2014-07-03 | Método de purificación del anticuerpo humanizado 9e4 |
Country Status (18)
Country | Link |
---|---|
US (2) | US10513555B2 (es) |
EP (2) | EP3524264A1 (es) |
JP (3) | JP6404338B2 (es) |
KR (1) | KR20160030247A (es) |
CN (1) | CN105492019B (es) |
AU (1) | AU2014285719A1 (es) |
CA (1) | CA2917097C (es) |
CL (1) | CL2015003801A1 (es) |
CU (2) | CU20170039A7 (es) |
ES (1) | ES2704440T3 (es) |
HK (1) | HK1223544A1 (es) |
IL (1) | IL243425A0 (es) |
MX (1) | MX2016000201A (es) |
PE (1) | PE20160868A1 (es) |
PH (1) | PH12015502788A1 (es) |
RU (1) | RU2016103079A (es) |
SG (1) | SG11201510601TA (es) |
WO (1) | WO2015001504A2 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE037811T2 (hu) | 2011-10-28 | 2018-09-28 | Prothena Biosciences Ltd | Alfa-szinukleint felismerõ humanizált antitestek |
WO2013112945A1 (en) | 2012-01-27 | 2013-08-01 | Neotope Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
US10562973B2 (en) | 2014-04-08 | 2020-02-18 | Prothena Bioscience Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
ES2964640T3 (es) | 2015-08-13 | 2024-04-08 | Amgen Inc | Filtración en profundidad cargada de proteínas de unión al antígeno |
RU2731418C2 (ru) * | 2015-09-28 | 2020-09-02 | Сучжоу Санкадия Биофармасьютикалз Ко., Лтд. | Стабильный фармацевтический препарат на основе антитела к pd-1 и его применение в медицине |
CN105127166A (zh) * | 2015-09-29 | 2015-12-09 | 中国华能集团清洁能源技术研究院有限公司 | 行走组件及具有其的光伏组件清洁装置 |
RU2748024C2 (ru) * | 2016-06-27 | 2021-05-19 | МорфоСис АГ | Составы на основе антитела к CD19 |
KR102593669B1 (ko) * | 2016-11-15 | 2023-10-25 | 하. 룬드벡 아크티에셀스카브 | 시누클레인병증의 치료를 위한 제제, 용도 및 방법 |
EP3555127A1 (en) | 2016-12-16 | 2019-10-23 | H. Lundbeck A/S | Agents, uses and methods |
US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
BR112019016374A2 (pt) | 2017-02-17 | 2020-04-07 | Bristol-Myers Squibb Company | anticorpos para alfa-sinucleína e usos dos mesmos |
JP2021502955A (ja) * | 2017-09-28 | 2021-02-04 | プロセナ・バイオサイエンシズ・リミテッド | シヌクレイン病の治療のための投与レジメン |
JP6831861B2 (ja) | 2019-01-25 | 2021-02-17 | 株式会社Grin | 歯科用測定器具、測定方法、及びアタッチメント器具 |
US11634485B2 (en) | 2019-02-18 | 2023-04-25 | Eli Lilly And Company | Therapeutic antibody formulation |
EP3786174A1 (en) * | 2019-08-27 | 2021-03-03 | Ichnos Sciences SA | Methods for antibody purification |
GB2587228B (en) * | 2019-09-20 | 2021-10-27 | Protein Ark Ltd | Biological sample purification apparatus, use of the same, and systems comprising the same |
EP4185612A1 (en) | 2020-07-23 | 2023-05-31 | Othair Prothena Limited | Anti-abeta antibodies |
CN114516914B (zh) * | 2020-11-19 | 2023-04-28 | 东莞市朋志生物科技有限公司 | 抗n末端脑钠肽前体的抗体和检测n末端脑钠肽前体的试剂和试剂盒 |
WO2023041524A2 (en) * | 2021-09-16 | 2023-03-23 | H. Lundbeck A/S | Compositions and methods for treating synucleinopathies |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2 Inc | Geänderte antikörper. |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
IE64738B1 (en) | 1990-03-20 | 1995-09-06 | Akzo Nv | Stabilized gonadotropin containing preparations |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
JP2000510813A (ja) | 1995-02-06 | 2000-08-22 | ジェネテイックス・インスティテュート・インコーポレイテッド | Il−12用処方 |
DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
CA2625839A1 (en) | 1999-02-05 | 2000-08-10 | Samsung Electronics Co., Ltd. | Image texture retrieving method and apparatus thereof |
CA2431600C (en) | 2000-12-12 | 2012-04-17 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
EP1539233B1 (en) | 2001-07-12 | 2011-04-27 | FOOTE, Jefferson | Super humanized antibodies |
ATE407674T1 (de) | 2002-04-09 | 2008-09-15 | Flamel Tech Sa | Orale pharmazeutische formulierung in form einer wässrigen suspension von mikrokapseln zur modifizierten freisetzung von amoxicillin |
CA2485342A1 (en) | 2002-05-13 | 2004-05-13 | Alexion Pharmaceuticals, Inc. | Humanized antibodies against the venezuelan equine encephalitis virus |
US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
US9034337B2 (en) | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
EP1567652B1 (de) | 2002-11-29 | 2007-08-22 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | Neue neomycin-phosphotransferase-gene und verfahren zur selektion von hochproduzierenden rekombinanten zellen |
PL1610820T5 (pl) | 2003-04-04 | 2014-01-31 | Genentech Inc | Preparaty zawierające wysokoskoncentrowane przeciwciała i białka |
US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
DE10338531A1 (de) | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Reklonierung von Produktionszellen |
US7674599B2 (en) | 2003-11-08 | 2010-03-09 | Elan Pharmaceuticals, Inc. | Methods of using antibodies to detect alpha-synuclein in fluid samples |
JP2007512846A (ja) | 2003-12-04 | 2007-05-24 | ゼンコー・インコーポレイテッド | 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物 |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
PL1820022T3 (pl) | 2004-11-10 | 2009-11-30 | Boehringer Ingelheim Pharma | Zastosowanie analizy metodą cytometrii przepływowej w optymalizacji strategii dla banków komórek jajnika chińskiego chomika |
CA2657953A1 (en) | 2005-07-19 | 2007-01-25 | University Of Rochester | Alpha-synuclein antibodies and methods related thereto |
US7662930B2 (en) * | 2005-12-06 | 2010-02-16 | Amgen Inc. | Polishing steps used in multi-step protein purification processes |
WO2008011348A2 (en) | 2006-07-14 | 2008-01-24 | Ac Immune S.A. | Humanized antibody against amyloid beta |
US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
EP2064242A1 (en) | 2007-02-23 | 2009-06-03 | Schering Corporation | Engineered anti-il-23p19 antibodies |
US8147833B2 (en) * | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
EP2118300B1 (en) | 2007-02-23 | 2015-05-27 | Prothena Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
MY148472A (en) | 2007-03-02 | 2013-04-30 | Boehringer Ingelheim Pharma | Improvement of protein production |
PT2132230E (pt) | 2007-03-22 | 2014-07-17 | Genentech Inc | Anticorpos apoptóticos anti-ige que se ligam ao ige ligado a membrana |
CN101668540A (zh) | 2007-03-22 | 2010-03-10 | 英克隆有限责任公司 | 稳定的抗体制剂 |
EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
EP2225275A4 (en) * | 2007-11-28 | 2013-04-03 | Medimmune Llc | PROTEIN FORMULATION |
ES2511844T3 (es) | 2007-12-21 | 2014-10-23 | F. Hoffmann-La Roche Ag | Formulación de anticuerpo |
PL2237803T3 (pl) | 2007-12-28 | 2015-12-31 | Prothena Therapeutics Ltd | Leczenie i profilaktyka amyloidozy |
EP2282758B1 (en) | 2008-04-29 | 2018-11-21 | BioArctic AB | Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders |
WO2009141239A1 (en) * | 2008-05-20 | 2009-11-26 | F. Hoffmann-La Roche Ag | A pharmaceutical formulation comprising an antibody against ox40l, uses thereof |
US20120276019A1 (en) | 2008-07-25 | 2012-11-01 | Diamedica Inc. | Tissue kallikrein for the treatment of parkinson's disease |
MX2011006422A (es) | 2008-12-19 | 2011-09-15 | Panima Pharmaceuticals Ag | Autoanticuerpos humanos anti-alfa-sinucleina. |
MX2012001268A (es) | 2009-07-28 | 2012-09-12 | Shire Human Genetic Therapies | Composiciones y metodos para tratar enfermedad de gaucher. |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
WO2011090720A2 (en) | 2009-12-29 | 2011-07-28 | Dr. Reddy's Laboratories Ltd | Purification of proteins |
EP2366714A1 (en) | 2010-03-03 | 2011-09-21 | Dr. Rentschler Holding GmbH & Co. KG | Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein |
TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
US9028830B2 (en) | 2010-04-08 | 2015-05-12 | JN Biosciences, LLC | Antibodies to CD122 |
TWI526161B (zh) | 2010-06-10 | 2016-03-21 | 亞培公司 | 包含鈣hmb及可溶性蛋白質之實質上透明營養液 |
PT2581113T (pt) | 2010-06-11 | 2018-07-04 | Univ Kyushu Nat Univ Corp | Anticorpo anti-tim-3 |
SI2593128T1 (en) | 2010-07-15 | 2018-08-31 | Adheron Therapeutics, Inc. | Humanized antibodies targeting the EC1 Kaderina-11 domain and associated compositions and procedures |
US20120264920A1 (en) * | 2010-10-11 | 2012-10-18 | Abbott Laboratories | Processes for purification of proteins |
EP2673635A4 (en) | 2011-02-07 | 2015-08-12 | Neotope Biosciences Ltd | IMMUNOTHERAPY THROUGH APOE |
WO2012160536A1 (en) | 2011-05-26 | 2012-11-29 | Dr Reddy's Laboratories Limited | Antibody purification |
AU2012272815B2 (en) | 2011-06-22 | 2017-09-07 | The General Hospital Corporation | Treatment of proteinopathies |
JP2014522843A (ja) | 2011-06-30 | 2014-09-08 | ジェネンテック, インコーポレイテッド | 抗c−met抗体製剤 |
SG10201604104PA (en) * | 2011-10-25 | 2016-07-28 | Prothena Therapeutics Ltd | Antibody formulations and methods |
HUE037811T2 (hu) | 2011-10-28 | 2018-09-28 | Prothena Biosciences Ltd | Alfa-szinukleint felismerõ humanizált antitestek |
RS63948B1 (sr) | 2011-10-31 | 2023-02-28 | Hoffmann La Roche | Formulacije anti-il13 antitela |
WO2013112945A1 (en) | 2012-01-27 | 2013-08-01 | Neotope Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
US9216219B2 (en) * | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
KR102036262B1 (ko) | 2012-08-29 | 2019-10-24 | 에프. 호프만-라 로슈 아게 | 혈액 뇌 장벽 셔틀 |
US8925815B2 (en) | 2012-09-05 | 2015-01-06 | Symbol Technologies, Inc. | Checkout system for and method of preventing a customer-operated accessory reader facing a bagging area from imaging targets on products passed through a clerk-operated workstation to the bagging area |
UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
US10562973B2 (en) | 2014-04-08 | 2020-02-18 | Prothena Bioscience Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
US10084674B2 (en) | 2015-09-09 | 2018-09-25 | International Business Machines Corporation | Virtual desktop operation and data continuity preservation |
-
2014
- 2014-07-02 US US14/322,797 patent/US10513555B2/en active Active
- 2014-07-03 PE PE2015002708A patent/PE20160868A1/es not_active Application Discontinuation
- 2014-07-03 WO PCT/IB2014/062806 patent/WO2015001504A2/en active Application Filing
- 2014-07-03 ES ES14752412T patent/ES2704440T3/es active Active
- 2014-07-03 SG SG11201510601TA patent/SG11201510601TA/en unknown
- 2014-07-03 EP EP18212531.0A patent/EP3524264A1/en active Pending
- 2014-07-03 RU RU2016103079A patent/RU2016103079A/ru not_active Application Discontinuation
- 2014-07-03 EP EP14752412.8A patent/EP3016677B1/en active Active
- 2014-07-03 CA CA2917097A patent/CA2917097C/en active Active
- 2014-07-03 JP JP2016522950A patent/JP6404338B2/ja active Active
- 2014-07-03 CU CUP2017000039A patent/CU20170039A7/es unknown
- 2014-07-03 CN CN201480047476.9A patent/CN105492019B/zh active Active
- 2014-07-03 KR KR1020167003163A patent/KR20160030247A/ko not_active Application Discontinuation
- 2014-07-03 MX MX2016000201A patent/MX2016000201A/es unknown
- 2014-07-03 AU AU2014285719A patent/AU2014285719A1/en not_active Abandoned
-
2015
- 2015-12-16 PH PH12015502788A patent/PH12015502788A1/en unknown
- 2015-12-31 IL IL243425A patent/IL243425A0/en unknown
- 2015-12-31 CL CL2015003801A patent/CL2015003801A1/es unknown
-
2016
- 2016-01-04 CU CUP2016000001A patent/CU20160001A7/es unknown
- 2016-10-12 HK HK16111756.3A patent/HK1223544A1/zh unknown
-
2018
- 2018-09-12 JP JP2018170393A patent/JP6854266B2/ja active Active
-
2019
- 2019-11-01 US US16/672,330 patent/US20200140534A1/en not_active Abandoned
-
2020
- 2020-10-23 JP JP2020177954A patent/JP2021020941A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN105492019B (zh) | 2020-02-11 |
RU2016103079A (ru) | 2017-08-07 |
CA2917097A1 (en) | 2015-01-08 |
US20200140534A1 (en) | 2020-05-07 |
CL2015003801A1 (es) | 2016-07-15 |
JP6404338B2 (ja) | 2018-10-10 |
PE20160868A1 (es) | 2016-09-24 |
CN105492019A (zh) | 2016-04-13 |
US10513555B2 (en) | 2019-12-24 |
US20150079074A1 (en) | 2015-03-19 |
WO2015001504A2 (en) | 2015-01-08 |
MX2016000201A (es) | 2016-05-31 |
CA2917097C (en) | 2022-05-03 |
EP3524264A1 (en) | 2019-08-14 |
PH12015502788A1 (en) | 2016-03-21 |
JP6854266B2 (ja) | 2021-04-07 |
HK1223544A1 (zh) | 2017-08-04 |
JP2021020941A (ja) | 2021-02-18 |
EP3016677A2 (en) | 2016-05-11 |
JP2016534052A (ja) | 2016-11-04 |
KR20160030247A (ko) | 2016-03-16 |
SG11201510601TA (en) | 2016-01-28 |
CU20170039A7 (es) | 2017-06-05 |
WO2015001504A3 (en) | 2015-08-06 |
IL243425A0 (en) | 2016-03-31 |
JP2019011339A (ja) | 2019-01-24 |
EP3016677B1 (en) | 2018-12-19 |
AU2014285719A1 (en) | 2016-01-21 |
ES2704440T3 (es) | 2019-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU20160001A7 (es) | Una formulación farmacéutica que comprende una versión quimérica, una versión de fragmentos no humanos o humanizados del anticuerpo 9e4 | |
PE20191242A1 (es) | Formulaciones de anticuerpo y metodos | |
PH12016502345A1 (en) | Anti-gitr antibodies and methods of use thereof | |
CO2017002689A2 (es) | Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del hígado graso no alchólico | |
CO6280464A2 (es) | Formulacion de anticuerpo cd20 | |
MX2022010623A (es) | Terapias de combinacion que comprenden un receptor quimerico de antigeno cd19 para el cancer. | |
MX2022006107A (es) | Metodos y composiciones para dosificacion en terapia celular adoptiva. | |
BR112018002196A2 (pt) | formulação anti-ifnar1 estável | |
IN2014CN04401A (es) | ||
BR112014011331A2 (pt) | anticorpos específicos para trop-2 e seus usos | |
AR088289A1 (es) | Composiciones para el tratamiento de la artritis reumatoide y metodos para su utilizacion | |
BR112017001183A2 (pt) | tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado | |
BR112017009398A2 (pt) | moléculas de ligação específicas para cd73 e seus usos | |
PE20151375A1 (es) | Compuestos ciclicos eter pirazol-4-il-heterociclil-carboxamida y metodos de utilizacion | |
MY176022A (en) | Acylated glucagon analogues | |
MX2016007825A (es) | Compuestos peptidomimeticos y conjugados de anticuerpo-farmaco de los mismos. | |
MX2016004907A (es) | Analogos del glucagon. | |
TN2012000560A1 (en) | Glucagon analogues | |
GT201200258A (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
AR085591A1 (es) | Anticuerpos del antigeno carcinoembrionario humano (cea) | |
GEP201706734B (en) | FORMULATION FOR ANTI-α4β7 ANTIBODY | |
AR083785A1 (es) | Anticuerpos humanos contra el ligando 1a de tipo tnf (factor de necrosis tumoral) humano (tl1a) | |
AR074360A1 (es) | Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion | |
CR10736A (es) | Composiciones y metodos relacionados con los anticuerpos del receptor del glucagon | |
JP2017510567A5 (es) |